Patient P-01802
Therapy response
Stable
Tolerance
Improving
GI state
Unstable
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
96%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S20
- Day 31 NP-02 recommended — Dietary Support Protocol NP-02
- Day 32 Patient accepted — Started NP-02 in the companion
- Day 42 GI symptom burden −14% vs expected — Dietary Support Protocol NP-02
- Day 48 Tolerance state changed — Unstable → Improving
- Day 50 Trajectory diverged from prediction — Observed response fell below the model's expected path.
What changed?
Trajectory began diverging from predicted response on Day 50.
Primary contributors, last 14 days
- GI instability+10
- Toxicity-6
- Inflammatory activity+4
- Treatment adherence-4
What helped?
- Dietary Support Protocol NP-02Day 31Result: symptom burden −14%
LIFE OS recommendation
GI Support Protocol GI-04
84%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 83% showed improvement
- median effect visible after 8 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓90
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 61 and rising
- WearableSleep 5.9 h, below personal baseline
- Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 43/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Inflammatory signalling ↑60
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 62
- WearableHRV 22 ms, trending down
- Autonomic recovery ↑45
- WearableResting HR 76 bpm
- WearableShort sleep window
- Drug metabolism and exposure ↑20
- BloodToxicity index 49
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- CYP2D6 Normal metabolizerExpected exposure
- MTHFR C677TReduced folate turnover
Microbiome
Shannon diversity 3 · butyrate capacity 43/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisHigh
- Bifidobacterium longumLow
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 16 ms
- Sleep
- 5.7 h
- Steps
- 4,051
- Resting HR
- 75 bpm
Daily log: GI score 61, nutritional resilience 41, adherence 38.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-01819 | 19% | S13 | — | — | 72 |
| P-01604 | 19% | S01 | — | — | 71 |
| P-01352 | 19% | S20 | — | — | 70 |
| P-01750 | 19% | S16 | — | — | 69 |
| P-01699 | 24% | S04 | GI-04 | improved | 69 |
| P-01508 | 19% | S18 | — | — | 68 |
| P-01509 | 20% | S17 | — | — | 68 |
| P-01817 | 19% | S14 | — | — | 67 |
| P-01877 | 26% | S01 | CR-01 | improved | 67 |
| P-01629 | 20% | S19 | — | — | 66 |
| P-01714 | 23% | S14 | GI-04 | improved | 66 |
| P-01858 | 29% | S14 | NP-02 | improved | 65 |